K
Kert D. Sabbath
Researcher at Yale University
Publications - 14
Citations - 2446
Kert D. Sabbath is an academic researcher from Yale University. The author has contributed to research in topics: Circulating tumor cell & Colorectal cancer. The author has an hindex of 6, co-authored 12 publications receiving 2214 citations. Previous affiliations of Kert D. Sabbath include University of Washington.
Papers
More filters
Journal ArticleDOI
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Steven J. Cohen,Cornelis J A Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. Craig Miller,Gerald V. Doyle,H. Tissing,Leon W.M.M. Terstappen,Neal J. Meropol +13 more
TL;DR: The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer and Baseline and follow-up CTC levels remained strong predictors of P FS and OS after adjustment for clinically significant factors.
Journal ArticleDOI
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
Steven J. Cohen,Cornelis J. A. Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. C. Miller,Gerald V. Doyle,H. Tissing,Leonardus Wendelinus Mathias Marie Terstappen,Neal J. Meropol +13 more
TL;DR: Baseline CTC count is an important prognostic factor within specific subgroups defined by treatment or patient characteristics, and unfavorable baseline CTC was associated with inferior PFS and overall survival.
Journal ArticleDOI
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
C. Aggarwal,Neal J. Meropol,Cornelis J. A. Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,N. Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. C. Miller,Steven J. Cohen +11 more
TL;DR: This study demonstrates that both CEA and CTCs contribute prognostic information for patients with metastatic colorectal cancer and in a multivariate analysis,CTCs at baseline but not CEA independently predicted survival and both C TCs and CEA independent predicted survival at 6-12 weeks.
Journal ArticleDOI
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
Gregory J. Riely,Shirish M. Gadgeel,Ivan Rothman,B. H. Saidman,Kert D. Sabbath,Kevie Feit,Mark G. Kris,Naiyer A. Rizvi +7 more
TL;DR: This phase 2 trial showed that TZT-1027 administered on days 1 and 8 of a 21-day cycle had no anticancer activity, and further development of TZt-1027 in patients with previously treated NSCLC is not warranted.
Journal ArticleDOI
Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer
Neal J. Meropol,Steven J. Cohen,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Michelle Miller,Gerald V. Doyle,H. Tissing,Leon W.M.M. Terstappen,C.J.A. Punt +9 more
TL;DR: This study investigates the hypothesis that CTC levels can predict clinical outcomes in patients with mCRC and stratified patients into unfavorable and favorable prognostic groups based on levels of =3 or <3 CTC per 7.5mL.